These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 33864122)

  • 21. Microenvironment and autophagy cross-talk: Implications in cancer therapy.
    Gomes LR; Vessoni AT; Menck CFM
    Pharmacol Res; 2016 May; 107():300-307. PubMed ID: 27037157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumour microenvironment and radiation response in sarcomas originating from tumourigenic human mesenchymal stem cells.
    D'Andrea FP; Safwat A; Burns JS; Kassem M; Horsman MR; Overgaard J
    Int J Radiat Biol; 2012 Jun; 88(6):457-65. PubMed ID: 22502876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells.
    Ahmed N; Escalona R; Leung D; Chan E; Kannourakis G
    Semin Cancer Biol; 2018 Dec; 53():265-281. PubMed ID: 30317036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reflected stemness as a potential driver of the tumour microenvironment.
    Rodrigues FS; Ciccarelli FD; Malanchi I
    Trends Cell Biol; 2022 Dec; 32(12):979-987. PubMed ID: 35589467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of the tissue factor pathway in the biology of tumor initiating cells.
    Garnier D; Milsom C; Magnus N; Meehan B; Weitz J; Yu J; Rak J
    Thromb Res; 2010 Apr; 125 Suppl 2():S44-50. PubMed ID: 20434004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting ion channels for cancer therapy by repurposing the approved drugs.
    Kale VP; Amin SG; Pandey MK
    Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2747-55. PubMed ID: 25843679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of Glypican-1 in the Tumour Microenvironment.
    Lund ME; Campbell DH; Walsh BJ
    Adv Exp Med Biol; 2020; 1245():163-176. PubMed ID: 32266658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting potassium channels in cancer.
    Huang X; Jan LY
    J Cell Biol; 2014 Jul; 206(2):151-62. PubMed ID: 25049269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heterogeneity and Plasticity of Breast Cancer Stem Cells.
    Sousa B; Ribeiro AS; Paredes J
    Adv Exp Med Biol; 2019; 1139():83-103. PubMed ID: 31134496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sortilin inhibition limits secretion-induced progranulin-dependent breast cancer progression and cancer stem cell expansion.
    Rhost S; Hughes É; Harrison H; Rafnsdottir S; Jacobsson H; Gregersson P; Magnusson Y; Fitzpatrick P; Andersson D; Berger K; Ståhlberg A; Landberg G
    Breast Cancer Res; 2018 Nov; 20(1):137. PubMed ID: 30454027
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The multifaceted role of exosomes in cancer progression: diagnostic and therapeutic implications [corrected].
    Sundararajan V; Sarkar FH; Ramasamy TS
    Cell Oncol (Dordr); 2018 Jun; 41(3):223-252. PubMed ID: 29667069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours.
    Beck B; Driessens G; Goossens S; Youssef KK; Kuchnio A; Caauwe A; Sotiropoulou PA; Loges S; Lapouge G; Candi A; Mascre G; Drogat B; Dekoninck S; Haigh JJ; Carmeliet P; Blanpain C
    Nature; 2011 Oct; 478(7369):399-403. PubMed ID: 22012397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIF expression and the role of hypoxic microenvironments within primary tumours as protective sites driving cancer stem cell renewal and metastatic progression.
    Philip B; Ito K; Moreno-Sánchez R; Ralph SJ
    Carcinogenesis; 2013 Aug; 34(8):1699-707. PubMed ID: 23740838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypoxia-Induced Resistance to Chemotherapy in Cancer.
    Minassian LM; Cotechini T; Huitema E; Graham CH
    Adv Exp Med Biol; 2019; 1136():123-139. PubMed ID: 31201721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The tumour microenvironment links complement system dysregulation and hypoxic signalling.
    Olcina MM; Kim RK; Melemenidis S; Graves EE; Giaccia AJ
    Br J Radiol; 2019 Jan; 92(1093):20180069. PubMed ID: 29544344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mitochondrial Retrograde Signalling and Metabolic Alterations in the Tumour Microenvironment.
    Yang D; Kim J
    Cells; 2019 Mar; 8(3):. PubMed ID: 30909478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update.
    Clara JA; Monge C; Yang Y; Takebe N
    Nat Rev Clin Oncol; 2020 Apr; 17(4):204-232. PubMed ID: 31792354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy and Inflammatory Cytokine Signalling in Cancer Cells and the Tumour Microenvironment.
    Edwardson DW; Parissenti AM; Kovala AT
    Adv Exp Med Biol; 2019; 1152():173-215. PubMed ID: 31456184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting K+ channels for cancer therapy.
    Conti M
    J Exp Ther Oncol; 2004 Jul; 4(2):161-6. PubMed ID: 15500011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapy Resistance in Cancers: Phenotypic, Metabolic, Epigenetic and Tumour Microenvironmental Perspectives.
    Zahan T; Das PK; Akter SF; Habib R; Rahman MH; Karim MR; Islam F
    Anticancer Agents Med Chem; 2020; 20(18):2190-2206. PubMed ID: 32748758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.